SLAM
BMRN icon

Swiss Life Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Swiss Life Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$956K Buy
16,713
+1,038
+7% +$56.9K ﹤0.01% 715
2026
Q1 		$885K Buy
15,675
+2,837
+22% +$165K ﹤0.01% 679
2025
Q4 		$763K Sell
12,838
-7,447
-37% -$405K ﹤0.01% 689
2025
Q3 		$1.1M Sell
20,285
-54,282
-73% -$3.1M 0.01% 621
2025
Q2 		$4.1M Buy
74,567
+58,073
+352% +$3.42M 0.02% 419
2025
Q1 		$1.17M Buy
16,494
+4,818
+41% +$324K 0.01% 595
2024
Q4 		$766K Buy
+11,676
New +$782K 0.01% 623
2024
Q3 		– Sell
-2,698
Closed -$222K – 632
2024
Q2 		$222K Sell
2,698
-900
-25% -$74.9K ﹤0.01% 572
2024
Q1 		$314K Sell
3,598
-1,145
-24% -$103K ﹤0.01% 514
2023
Q4 		$459K Sell
4,743
-199
-4% -$17.6K 0.01% 581
2023
Q3 		$437K Sell
4,942
-34,856
-88% -$3.1M 0.01% 583
2023
Q2 		$3.45M Buy
39,798
+1,063
+3% +$100K 0.05% 392
2023
Q1 		$3.77M Buy
38,735
+2,649
+7% +$275K 0.06% 375
2022
Q4 		$3.75M Sell
36,086
-1,376
-4% -$129K 0.06% 321
2022
Q3 		$3.18M Buy
37,462
+1,740
+5% +$155K 0.05% 358
2022
Q2 		$2.97M Buy
35,722
+6,263
+21% +$499K 0.05% 382
2022
Q1 		$2.27M Sell
29,459
-180
-0.6% -$15.1K 0.03% 406
2021
Q4 		$2.62M Hold
29,639
– – 0.03% 406
2021
Q3 		$2.29M Hold
29,639
– – 0.03% 409
2021
Q2 		$2.47M Sell
29,639
-2,163
-7% -$171K 0.03% 420
2021
Q1 		$2.4M Sell
31,802
-614
-2% -$50.2K 0.03% 404
2020
Q4 		$2.84M Hold
32,416
– – 0.04% 389
2020
Q3 		$2.46M Buy
32,416
+2,570
+9% +$260K 0.04% 307
2020
Q2 		$3.68M Hold
29,846
– – 0.06% 219
2020
Q1 		$2.53M Buy
29,846
+1,749
+6% +$151K 0.05% 249
2019
Q4 		$2.38M Hold
28,097
– – 0.05% 320
2019
Q3 		$1.89M Buy
28,097
+2,584
+10% +$199K 0.02% 358
2019
Q2 		$2.18M Buy
25,513
+7,179
+39% +$614K 0.03% 309
2019
Q1 		$1.63M Buy
+18,334
New +$1.7M 0.02% 332
2018
Q3 		– Sell
-21,041
Closed -$1.98M – 538
2018
Q2 		$1.98M Buy
+21,041
New +$1.84M 0.03% 305

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swiss Life Asset Management's BMRN Position: Q2 2026 in Review

Swiss Life Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 6.6% in Q2 2026, buying an estimated $56.9K and bringing the position to 16,713 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #715.

Swiss Life Asset Management first reported a position in BMRN in Q2 2018 and has held it in 30 quarters since. The position peaked at $4.1M in Q2 2025. 413 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Swiss Life Asset Management held 16,713 shares of BioMarin Pharmaceuticals worth $956K as of Q2 2026.
  • Swiss Life Asset Management bought 1,038 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $56.9K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #715 holding.
  • Swiss Life Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
  • Swiss Life Asset Management's BioMarin Pharmaceuticals position peaked at $4.1M in Q2 2025.
  • 413 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.